Summary

Over 250 branded drugs in the U.S. will see price increases starting Jan. 1, 2025, with most hikes below 10% and a median increase of 4.5%.

Key companies like Pfizer, Bristol Myers Squibb, and Sanofi are raising prices on treatments for COVID-19, cancer, and vaccines, citing R&D costs and inflation.

Some prices, such as Merck’s diabetes drugs, will be reduced.

Critics highlight that U.S. drug prices remain the highest globally, while manufacturers face pressure to moderate year-over-year price hikes.

  • @[email protected]
    32•21 days ago

    The pharma industry is doing the US public a service by getting people used to paying Trump’s tariffs early.

    • @[email protected]
      7•21 days ago

      Now now, I think you know these fine American institutions won’t be passing up another opportunity to raise prices once those tariffs hit. This is a double dip.